Sanofi SA ADR
SNY: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| %D | LOCK|ggS#d | LOCK|Jm>j@t |
Led by Dupixent, Solid Immunology Position Helps Support Steady Long-Term Growth for Sanofi
Business Strategy and Outlook
Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a wide economic moat. Growth of existing products and new product launches should help offset upcoming patent losses.
